APA (7th ed.) Citation

SS, J., DVT, C., TG, K., JD, P., MM, Z., A, S., . . . MR, S. (2020). Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(1), 18. https://doi.org/10.1158/1078-0432.CCR-19-1483

Chicago Style (17th ed.) Citation

SS, Joshi, et al. "Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 26, no. 1 (2020): 18. https://doi.org/10.1158/1078-0432.CCR-19-1483.

MLA (9th ed.) Citation

SS, Joshi, et al. "Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 26, no. 1, 2020, p. 18, https://doi.org/10.1158/1078-0432.CCR-19-1483.